Poor prognostic implications of high RRM2 expression is of interest since it may indicate which subsets of NSCLC patients could benefit more from antimetabolite or siRNA therapy [46] that interferes with RNR function. The gene discussed is NR2E3; the disease is non-small cell lung carcinoma.